EPO GmbH

EPO is a Berlin-based preclinical contract research organization (CRO) that has been in business for almost 30 years. We offer customized, comprehensive preclinical oncology and immuno-oncology services for developing novel anti-cancer drugs. Our portfolio includes over 1,000 well-characterized PDX models of approximately 17 cancer types (solid tumors and leukemia), as well as CDX and syngeneic tumor models. Additionally, EPO has extensive experience establishing humanized models. 

We have expertise in: 

Oncology, Immuno-Oncology, PDX, CDX, syngeneic, IO, Tumor Imaging,  Incucyte, Flow Cytometry, FACS, Cell Biology, in vitro, in vivo,  Histology, Model Selection, Humanized mouse, Oncolytic viruses,  Radiation Oncology, 2D and 3D culture, Molecular Biology, Tumor Bank,  Biomarker, Target ID, PK, PD, Drug Discovery, pre-clinical, preclinical,  Cell Therapy, CAR-T, CGT, Cell and Gene Therapy, Cytotoxicity,  Xenograft, GEMMs, Clinical data set, Adoptive Cell Therapy, Anticancer  vaccines, BiTEs, bispecific, TC engager, ADC, TNBC